Date and Time: Saturday, December 10 at 4:00 p.m. CST / 5:00 p.m. EST / 23:00 CET
- Date and Time: Saturday, December 10 at 4:00 p.m. CST / 5:00 p.m. EST / 23:00 CET
Affimed will host an investor event to review AFM13 clinical data and development plans in CD30 expressing malignancies.
- The investor event will take place in-person and virtually and a webcast of the event will be available in the Webcasts section on the Investors page of Affimeds website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/ .
- To reserve your place in the live event, please contact Alex Fudukidis via e-mail at [email protected] .
- AFM13 is a CD30/CD16A bispecific Innate Cell Engager (ICE) that is investigated in Hodgkin Lymphoma (HL) and T cell lymphoma (TCL).